The first participant has been dosed in Regimen I of the HEALEY ALS Platform Trial evaluating Neurizon Therapeutics’ lead candidate NUZ-001 to treat ALS.
The Calmer Co International has taken two major steps to accelerate its growth in the US with a kava master supply agreement and completing a placement for $1.6 million.